ArticleMolecular therapy. Nucleic acids2020
hsa_circ_001653 Implicates in the Development of Pancreatic Ductal Adenocarcinoma by Regulating MicroRNA-377-Mediated HOXC6 Axis.
Article in Molecular therapy. Nucleic acids, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 58 citations in OpenAlex.
- METTL3-dependent m6A methylation of circCEACAM5 fuels pancreatic cancer progression through DKC1 activation.Cellular and molecular life sciences : CMLS · 2025Article
- Review
- Circular RNA hsa_circ_0007367 promotes the progression of pancreatic ductal adenocarcinoma by sponging miR-6820-3p and upregulating YAP1 expression.Cell death & disease · 2022Article
- Biological functions, mechanisms, and clinical significance of circular RNA in pancreatic cancer: a promising rising star.Cell & bioscience · 2022Review
- Roles of circular RNAs in the pathogenesis and treatment of pancreatic cancer.Frontiers in cell and developmental biology · 2022Review
- HOXC6 Regulates the Epithelial-Mesenchymal Transition through the TGF-Journal of oncology · 2022Article
- Noncoding RNAs in tumor metastasis: molecular and clinical perspectives.Cellular and molecular life sciences : CMLS · 2021Review
- Long non-coding RNAs and circular RNAs in tumor angiogenesis: From mechanisms to clinical significance.Molecular therapy oncolytics · 2021Review
- CircRNAs and their regulatory roles in cancers.Molecular medicine (Cambridge, Mass.) · 2021Review
- Circular RNA CircEYA3 induces energy production to promote pancreatic ductal adenocarcinoma progression through the miR-1294/c-Myc axis.Molecular cancer · 2021Article
- Non-Coding RNAs in Pancreatic Cancer Diagnostics and Therapy: Focus on lncRNAs, circRNAs, and piRNAs.Cancers · 2021Review
- S100P acts as a target of miR-495 in pancreatic cancer through bioinformatics analysis and experimental verification.The Kaohsiung journal of medical sciences · 2021Article
- Circ-0005105 activates COL11A1 by targeting miR-20a-3p to promote pancreatic ductal adenocarcinoma progression.Cell death & disease · 2021Article
- Angiogenesis-related non-coding RNAs and gastrointestinal cancer.Molecular therapy oncolytics · 2021Review
- Circ-MBOAT2 knockdown represses tumor progression and glutamine catabolism by miR-433-3p/GOT1 axis in pancreatic cancer.Journal of experimental & clinical cancer research : CR · 2021Article
- Current State of "Omics" Biomarkers in Pancreatic Cancer.Journal of personalized medicine · 2021Review
- The inhibiting effects of microRNA-429 on the progression of pancreatic ductal adenocarcinoma cells by inhibiting epithelial mesenchymal transition.American journal of translational research · 2021Article
- Circular RNA in pancreatic cancer: a novel avenue for the roles of diagnosis and treatment.Theranostics · 2021Review
- Recent Advances in the Potential Use of Circular RNA for the Diagnosis and Treatment of Pancreatic Cancer.Cancer management and research · 2021Review
- Circular RNAs as novel potential biomarkers for pancreatic cancer.Journal of Cancer · 2021Review
Corrections and comments
- Retraction · 2022-11-04Falsification/Fabrication of Image · Investigation by Company/Institution · Investigation by Third Party · Manipulation of Images · Misconduct - Official Investigation(s) and/or Finding(s) · Misconduct by Author · · see https://pubpeer.com/publications/4661DB0D531C610DD10E8EAD3C2D97 and https://www.nsfc.gov.cn/publish/portal0/tab434/info87591.htm
- Retracted
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pancreatic ductal adenocarcinoma (PDAC) is an extremely aggressive pancreatic cancer with poor survival rate. Circular RNAs (circRNAs) signatures have been identified in some human cancers, but there are little data concerning their presence in PDAC. We investigated the role of hsa_circ_001653, a newly identified circRNA, in the development of PDAC. hsa-circ-001653 expression was measured in 83 paired normal and tumor tissues surgically resected from PDAC patients. Phenotypic changes of PDAC cells were evaluated by assays for cell viability, cell cycle, invasion, and apoptosis. Tube-like structure formation of human umbilical vein endothelial cells (HUVECs) was examined in the presence of PDAC cells. Cross-talk between hsa_circ_001653 and microRNA-377 (miR-377)/human homeobox C6 (HOXC6) was assessed using dual-luciferase reporter assay, Ago2 immunoprecipitation, and northern blot analysis. Nude mice were inoculated with human PDAC cells for in vivo analysis. hsa_circ_001653 was an upregulated circRNA in PDAC. Silencing of hsa_circ_001653 in PDAC cells via RNA interference inhibited cell viability, cell-cycle progression, in vitro angiogenesis, and invasive properties, showing a pro-apoptotic effect. hsa_circ_001653 was found to bind to miR-377, which in turn repressed HOXC6 expression. Inhibition of miR-377 by its specific inhibitor restored cell viability, cell-cycle progression, in vitro angiogenesis, and invasive properties in PDAC cells lacking endogenous hsa_circ_001653. When nude mice were inoculated with human PDAC cells, inhibition of hsa_circ_001653 had a therapeutic effect. Collectively, the present study provides an enhanced understanding of hsa_circ_001653 as a therapeutic target for PDAC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.